| Study Period | 2019 - 2030 |
| Market Size (2025) | USD 1.50 Billion |
| Market Size (2030) | USD 2.36 Billion |
| CAGR (2025 - 2030) | 9.46 % |
| Fastest Growing Market | Asia-Pacific |
| Largest Market | North America |
| Market Concentration | Medium |
Major Players
*Disclaimer: Major Players sorted in no particular order |
PEGylated Proteins Market Analysis
The Global PEGylated Proteins Market size is estimated at USD 1.50 billion in 2025, and is expected to reach USD 2.36 billion by 2030, at a CAGR of 9.46% during the forecast period (2025-2030).
The impact of COVID-19 on the PEGylated proteins market was moderate. According to the study published in Biomaterial in June 2021, PEGylated nanoparticle albumin-bound (PNAB) -steroidal ginsenoside can effectively lower histone H4 and NETosis-related factors in the plasma and ameliorate SREBP2-mediated systemic inflammation in SARS-CoV-2 ICU patients. PNAB-steroidal ginsenoside medications may be useful in treating symptoms associated with severe SARS-CoV-2 patients, such as coagulation and cytokine storm. Furthermore, according to an article published by PubMed Central in August 2021, a phase III clinical trial showed the efficacy and safety of pegylated interferon alpha-2b (PEG IFN-α2b) in patients with moderate COVID-19 infections. Thus, given the extensive research activities based on PEGylation technology, the COVID-19 pandemic impacted the market moderately; however, as the pandemic has subsided currently, the studied market is expected to have stable growth during the forecast period of the study.
The major factor attributing to the growth of the market is the increasing prevalence of chronic diseases like cancer, kidney diseases, and rheumatoid arthritis. According to the data from the American Cancer Society 2022, an estimated 1,908,030 new cancer cases are expected to be diagnosed in the United States in 2022. Moreover, as per the same source, among all cancers, digestive system cancer is expected to account for 343,040 cases, breast cancer is expected to account for 290,560 new cancer cases, followed by respiratory system cancer, with 254,850 new cases in 2022. Additionally, as per the Global HIV and AIDS Statistics, 2022 fact sheet by UNAIDS, 38.4 million people globally were living with HIV in 2021. Thus, with the growing burden of chronic and infectious diseases such as cancer, HIV, tuberculosis, and others globally, the demand for developing medicine is also expected to increase, which will boost the research on protein, thus driving the PEGylated protein market.
Furthermore, biotechnology and pharmaceutical companies' growing investments in research and development programs are boosting the market growth. For instance, in March 2022, Flow Eighteen38, a protein sciences division created to facilitate and accelerate antibody characterization and protein purification projects, announced a EUR 5 million (USD 5.58 million) investment into its protein production and biophysical characterization capabilities and services from its parent company, CRO FairJourneyBiologics S.A. In addition, there is rising adoption of protein-based drugs over non-protein-based drugs wherein PEGylation increases the circulation and half-life of the proteins, improving the efficacy.
Therefore, the factors above, such as the growing burden of chronic and infectious diseases such as cancer, HIV, tuberculosis, and others globally, and the growing investments in research and development programs by biotechnology and pharmaceutical companies, the market is expected to experience growth. However, the high drug failure rates and drug recalls are the major factors impeding the market's growth.
PEGylated Proteins Market Trends
The Colony-stimulating Factors Segment is Expected to Grow at a Significant Rate Over the Forecast Period
Colony-stimulating factors are substances that accelerate the production of blood cells and elevate their ability to function. They do not directly influence tumors but have a role in stimulating blood cells, and hence, these factors can be beneficial in supporting a person's immune system during cancer treatment.
According to the research article published in Frontier in Oncology in April 2022, a half-dose of prophylactic granulocyte-colony stimulating factor (G-CSF) can effectively and safely prevent neutropenia in patients with various malignancies who have an intermediate risk of febrile neutropenia (FN) combined with 1 patient-specific risk during chemotherapy. Thus, the above benefits of the colony-stimulating factors in the treatment of tumors are expected to boost segment growth.
Furthermore, the market growth of the segment is due to the increasing incidence of cancer across the globe, and the usage of peptide treatment for cancer. According to the data published by National Cancer Center Japan in June 2022, an estimated 1,019,000 new cases of cancer are expected in Japan in 2022, out of which 158,200 new cases of colon/rectum cancer, 132,100 cases of stomach cancer, 128,800 cases of lung/trachea cancer, 96,400 cases of prostate cancer, and 95,000 cases of breast cancer are expected. Furthermore, according to an article published by NCBI in March 2022, China is experiencing a greater incidence of cancers. In 2022 it is expected that there will be approximately 4,820,000 new cancer cases in China, in which the most common is lung cancer. Thus, the high incidence of cancer surges the need for colony-stimulating factors in its effective treatment and thus drives segment growth.
Furthermore, the increased awareness among patients and healthcare professionals regarding the adverse effects of other methods of cancer treatments, such as chemotherapy and radiation therapy, is a major factor for the growing focus on alternative therapeutics such as pegylated peptide-based drugs. Hence, the aforementioned factors are expected to positively drive the growth of the colony-stimulating factors segment over the forecast period.
Understand The Key Trends Shaping This Market
Download PDF
North America Holds a Significant Share of the Market and is Expected to do the Same Over the Forecast Period
North America is expected to hold a significant share of the overall PEGylated protein market throughout the forecast period. The presence of key players, the high prevalence of chronic diseases in the region, established healthcare infrastructure, and growing awareness of advanced treatment options among the American population are some of the key factors accountable for its large share in the market. In November 2022, the Canadian Cancer Society data stated, it was estimated that 233,900 people will be diagnosed with cancer in 2022, and this growth in incidence is largely due to Canada's growing and aging population. Thus, the growing prevalence of chronic diseases is expected to rise in research and development activity driving the growth of the market in the region over the forecast period.
Furthermore, the rising geriatric population and the high incidence of chronic diseases are also expected to play a vital role in the growth of the studied market. According to the estimates of the American Cancer Society, in 2022, it was expected that 79,000 new instances of kidney cancer are likely to be diagnosed in the United States in 2022, including 50,290 cases in males and 28,710 cases in women. The top 10 malignancies for both men and women include kidney cancer. Men have about a 1 in 46-lifetime risk of having kidney cancer (2.02%). For women, the lifetime risk is approximately 1 in 80. (1.03%). Thus, the growing prevalence of chronic diseases in the region is likely to propel the growth of the market.
Furthermore, beneficial government initiatives and an increase in the number of research partnerships are some of the factors expected to drive market growth. For instance, in February 2021, Nautilus merged with Arya III, a special purpose acquisition company (SPAC), with an initial investment of USD 350 million to ramp up work developing its protein analysis technology for drug discovery and diagnostic applications.
Hence, due to the aforementioned factors such as the increasing prevalence of chronic diseases in the region and beneficial government initiatives and an increase in the number of research partnerships, are expected to boost the market growth in the region.
Get Analysis on Important Geographic Markets
Download PDF
PEGylated Proteins Industry Overview
The PEGylated proteins market is moderately consolidated and consists of a few major players. Some companies currently dominating the market are Merck KGaA, Thermo Fisher Scientific Inc., NOF America Corporation, JenKem Technology USA Inc., and Creative PEGworks, among others. The companies have been following various strategies such as acquisitions, partnerships, investments in research activities, and new product launches to sustain themselves among the competitors in the global market.
PEGylated Proteins Market Leaders
-
Merck KGaA
-
Thermo Fisher Scientific, Inc
-
NOF America Corporation
-
JenKem Technology USA, Inc
-
Creative PEGworks
- *Disclaimer: Major Players sorted in no particular order
Need More Details on Market Players and Competiters?
Download PDF
PEGylated Proteins Market News
- November 2022: Nektar Therapeutics announced the first presentation of preclinical data for NKTR-288 at the 2022 Society for Immunotherapy of Cancer (SITC) Annual Meeting. NKTR-288 is a novel polyethylene glycol (PEG)-the conjugate of interferon-gamma (IFN-γ); it is designed to modify the binding of IFN-γ to its substrates and optimize the duration of IFN-γ signaling. IFN-γ is a cytokine that induces cellular antigen presentation and enhances tumor antigen-specific cytotoxic T-cell response and may have applications in several therapeutic areas, including oncology and infectious diseases.
- July 2022: The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) issued a favorable opinion, recommending the approval of doxorubicin hydrochloride (Celdoxome pegylated liposomal) for the treatment of metastatic breast cancer, advanced ovarian cancer, progressive multiple myeloma, and AIDS-related Kaposi's sarcoma.
- February 2022: Merck KGaA announced the acquisition of Exelead, a biopharmaceutical CDMO specializing in PEGylated products and complex injectable formulations, including Lipid Nanoparticle (LNP) based drug delivery technology.
PEGylated Proteins Industry Segmentation
As per the scope of the report, PEGylation is the process of binding or alteration of biological molecules by conjugation with polyethylene glycol is known as PEGylation. PEGylation enhances the stability and solubility of the drug and declines immunogenicity by changing the molecule's electrostatic binding, confirmation, and hydrophobicity. The PEGylated Proteins Market is Segmented by Product Type (PEGylation Kits and Reagents (Monofunctional Linear PEGs, Bifunctional PEGs), Services, and Other Product Types), Protein Type (Colony-stimulating Factor, Interferon, Erythropoietin, and Other Protein Types), End User (Pharmaceutical and Biotechnology Companies, Contract Research Organizations, and Academic Research Institutes), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The market report also covers the estimated sizes and trends for 17 countries across major regions globally. The report offers the value (USD) for the above segments.
| By Product Type | PEGylation Kits and Reagents | Monofunctional Linear PEGs | |
| Bifunctional PEGs | |||
| Services | |||
| Other Product Types | |||
| By Protein Type | Colony-stimulating Factors | ||
| Interferons | |||
| Erythropoietin | |||
| Other Protein Types | |||
| By End User | Pharmaceutical and Biotechnology Companies | ||
| Contract Research Organizations | |||
| Academic Research Institutes | |||
| Geography | North America | United States | |
| Canada | |||
| Mexico | |||
| Europe | Germany | ||
| United Kingdom | |||
| France | |||
| Italy | |||
| Spain | |||
| Rest of Europe | |||
| Asia-Pacific | China | ||
| Japan | |||
| India | |||
| Australia | |||
| South Korea | |||
| Rest of Asia-Pacific | |||
| Middle East and Africa | GCC | ||
| South Africa | |||
| Rest of Middle East and Africa | |||
| South America | Brazil | ||
| Argentina | |||
| Rest of South America | |||
Need A Different Region or Segment?
Customize Now
Global PEGylated Proteins Market Research Faqs
How big is the Global PEGylated Proteins Market?
The Global PEGylated Proteins Market size is expected to reach USD 1.50 billion in 2025 and grow at a CAGR of 9.46% to reach USD 2.36 billion by 2030.
What is the current Global PEGylated Proteins Market size?
In 2025, the Global PEGylated Proteins Market size is expected to reach USD 1.50 billion.
Who are the key players in Global PEGylated Proteins Market?
Merck KGaA, Thermo Fisher Scientific, Inc, NOF America Corporation, JenKem Technology USA, Inc and Creative PEGworks are the major companies operating in the Global PEGylated Proteins Market.
Which is the fastest growing region in Global PEGylated Proteins Market?
Asia-Pacific is estimated to grow at the highest CAGR over the forecast period (2025-2030).
Which region has the biggest share in Global PEGylated Proteins Market?
In 2025, the North America accounts for the largest market share in Global PEGylated Proteins Market.
What years does this Global PEGylated Proteins Market cover, and what was the market size in 2024?
In 2024, the Global PEGylated Proteins Market size was estimated at USD 1.36 billion. The report covers the Global PEGylated Proteins Market historical market size for years: 2019, 2020, 2021, 2022, 2023 and 2024. The report also forecasts the Global PEGylated Proteins Market size for years: 2025, 2026, 2027, 2028, 2029 and 2030.
Our Best Selling Reports
Global PEGylated Proteins Industry Report
Statistics for the 2025 Global PEGylated Proteins market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Global PEGylated Proteins analysis includes a market forecast outlook for 2025 to 2030 and historical overview. Get a sample of this industry analysis as a free report PDF download.
